Home > Boards > US Listed > Medical - Drugs >

Humanigen Inc. (HGEN)

HGEN RSS Feed
Add HGEN Price Alert      Hide Sticky   Hide Intro
Moderator: rstar, MWM, Taurus69, shajandr, TheGreatSwami , Engineering_Simple
Search This Board: 
Last Post: 3/1/2021 6:44:55 AM - Followers: 243 - Board type: Free - Posts Today: 2

https://www.humanigen.com/
 

COMPANY OVERVIEW

Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms.  As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.

We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective.  In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.

The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate.  A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma.  The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.  The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT.  The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline. 

 
 
 




Mayo Clinic Study of Humanigen’s Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients

June 15, 2020

https://www.businesswire.com/news/home/20200615005324/en/Mayo-Clinic-Study-Humanigen%E2%80%99s-Lenzilumab-Shows-Rapid


Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia 

https://clinicaltrials.gov/ct2/show/NCT04351152 
 

Disintegrating coronavirus

Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets

https://www.clinicaltrialsarena.com/comment/anti-gm-csf-antibodies-covid-19/ 
 
National Institutes of Health Selects Humanigen’s Lenzilumab for its COVID-19 Big Effect Trial

July 27, 2020

https://www.humanigen.com/press/National-Institutes-of-Health-Selects-Humanigen%E2%80%99s-Lenzilumab-for-its-COVID-19-Big-Effect-Trial







 
HGEN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
HGEN News: Humanigen to Present at Multiple Investor Conferences in March 02/25/2021 07:30:00 AM
HGEN News: Statement of Changes in Beneficial Ownership (4) 02/24/2021 06:28:01 PM
HGEN News: Statement of Changes in Beneficial Ownership (4) 02/19/2021 06:02:40 PM
HGEN News: Statement of Changes in Beneficial Ownership (4) 02/16/2021 06:54:53 PM
HGEN News: Amended Statement of Ownership (sc 13g/a) 02/16/2021 03:08:01 PM
PostSubject
#24524  Sticky Note There's a prevailing belief from a growing number Engineering_Simple 01/21/21 03:30:04 PM
#18681  Sticky Note Company Highlights/Phase 3/NIH Big Effect Trial MWM 09/29/20 07:11:49 AM
#11863  Sticky Note National Institutes of Health Selects Humanigen’s Lenzilumab for kairos 07/27/20 04:07:41 PM
#10590  Sticky Note They will unblind the trial for an interim Millstone 07/07/20 11:21:58 PM
#25502   Wow!! Yooo 03/01/21 06:44:55 AM
#25501   The coronavirus crisis was a huge catalyst for Knuckle Sandwich 03/01/21 12:01:02 AM
#25500   What is a Data Room? A data room is EdF 02/27/21 09:47:57 PM
#25499   I fell off my chair when I heard Corundum 02/27/21 08:35:46 PM
#25498   Roth starts March 5th lthomp52 02/27/21 07:14:58 PM
#25497   ...the Company’s management team will present and host talleyrand 02/27/21 04:30:50 PM
#25496   Big week next week... (but then again we RobinX 02/27/21 01:21:09 PM
#25495   What do you mean by data room setup? aquaspin 02/27/21 11:39:56 AM
#25494   Data Room Set up. Did anyone eom7 02/27/21 10:45:55 AM
#25493   "Best possible result for HGEN". I believe that eom7 02/27/21 10:36:53 AM
#25492   Did you atleast take a look at the Toohie 02/26/21 08:41:52 PM
#25491   Thanks for putting these together! Very informative and Knuckle Sandwich 02/26/21 06:59:55 PM
#25490   The thing I would most like to see cowtown jay 02/26/21 06:01:59 PM
#25489   I'm hoping the premium drops as we get nelskof 02/26/21 04:51:07 PM
#25488   Also,Looks like somebody took a bite of the Gustyhu 02/26/21 04:07:30 PM
#25487   Could be a coupe for Avid CDMO if Gustyhu 02/26/21 04:05:18 PM
#25486   I was just looking at them recently, but cowtown jay 02/26/21 03:58:28 PM
#25485   Big buys into close! $HGEN$ Rockurstocks 02/26/21 03:49:33 PM
#25484   For anyone that's interested,CDMO's chart is really moving Gustyhu 02/26/21 03:31:09 PM
#25483   God help me, I've bought these latest dips Gustyhu 02/26/21 02:34:54 PM
#25482   That's good info. I forgot to mention nelskof 02/26/21 02:19:40 PM
#25481   I've been confident for months but yesterday had PhrmaBro 02/26/21 01:51:51 PM
#25480   Great Notes! What a F-ing Great CC it MWM 02/26/21 01:45:11 PM
#25479   At least you didn't register and then get Corundum 02/26/21 01:40:57 PM
#25478   yep...then bought by the big boys to scale talleyrand 02/26/21 01:32:18 PM
#25477   You almost always can bet on a company Gustyhu 02/26/21 01:18:14 PM
#25476   I’m sure there are “others” with much investment RobinX 02/26/21 12:08:00 PM
#25475   agreed - Dale has about as relevant of falqie 02/26/21 12:05:05 PM
#25474   They addressed the pseudo-scientific questions I threw in falqie 02/26/21 12:01:59 PM
#25473   Did Cameron make a comment on the status lthomp52 02/26/21 12:00:41 PM
#25472   Compare this exec team to any other, world RobinX 02/26/21 11:59:59 AM
#25471   Not gonna lie, after watching Otilimab and Merck nelskof 02/26/21 11:52:33 AM
#25470   OWS has been a great platform for partnerships. Engineering_Simple 02/26/21 11:43:29 AM
#25469   Changes in endpoint target etc along the way Engineering_Simple 02/26/21 11:37:47 AM
#25468   Q&A on what the lenz value proposition is Engineering_Simple 02/26/21 11:30:47 AM
#25467   strong data mining capabilities, with segmentation and targeting falqie 02/26/21 11:26:59 AM
#25466   LOL, I might have to do something. cowtown jay 02/26/21 11:26:39 AM
#25465   Outside of what’s already a substantial revenue stream Engineering_Simple 02/26/21 11:24:17 AM
#25464   Durrant, nelskof 02/26/21 11:23:56 AM
#25463   Durrant only willing to commit to data by nelskof 02/26/21 11:18:03 AM
#25462   Cameron making a stark departure from his optimistic falqie 02/26/21 11:17:49 AM
#25461   Regarding Merck, nelskof 02/26/21 11:16:55 AM
#25460   Regarding GSK... nelskof 02/26/21 11:15:28 AM
#25459   VeryJerry Bullish now $HGEN FYI according to CMO - GSK trial MWM 02/26/21 11:14:31 AM
#25458   Same here, I emailed asking when a replay Knuckle Sandwich 02/26/21 11:09:35 AM
#25457   LOL, Chappell going straight in on GSK. 90 falqie 02/26/21 11:09:20 AM
#25456   Think $1B sales in ‘21 is possible Dr. Engineering_Simple 02/26/21 11:08:56 AM
#25455   Detailed notes please like you studying for a RobinX 02/26/21 11:08:29 AM
#25454   Ukkkhh, said 100 person capacity for me. Wth! RobinX 02/26/21 11:07:50 AM
#25453   I'm in, Chappel is going to talk about nelskof 02/26/21 11:04:41 AM
PostSubject
Consent Preferences